Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug candidate BI 3034701 targets obesity in japanese adults

NCT ID NCT07693231

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-stage trial investigates a new drug called BI 3034701 in Japanese adults. Part 1 includes people with obesity or overweight (BMI 27 or higher) to see if the drug is safe and how the body processes it over 16 weeks. Part 2 includes healthy volunteers with a BMI between 23 and 27 to check safety and drug levels over 7 weeks. The study aims to gather initial information on safety, tolerability, and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
BI 3034701
What this could lead to
If successful, this could point toward a new treatment option for obesity and overweight in Japanese adults.
What could go wrong
This is an early phase 1 trial with only 48 participants, so the drug may not prove safe or effective. Side effects are possible and not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY OBESITY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fukuoka Mirai Hospital

    RECRUITING

    Fukuoka, Fukuoka, 813-0017, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SOUSEIKAI Hakata Clinic

    RECRUITING

    Fukuoka, Fukuoka, 812-0025, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • SOUSEIKAI Sumida Hospital

    RECRUITING

    Tokyo, Sumida-ku, 130-0004, Japan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.